Oncology Based In-vivo CRO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 By Indication (Blood Cancer, Solid Tumor), By Model (Syngeneic Model, Patient Derived Xenograft, Xenograft), By Region and Competition

Market Overview

Key Market Drivers

Rising Prevalence of Cancer

Advancements in Cancer Research

Key Market Challenges

Complexity of Cancer Research

High Costs

Key Market Trends

Personalized Medicine

Digitalization and Data Analytics

Segmental Insights

Indication

With a 47.08% market share in 2022, the solid tumors segment dominates the Oncology Based In-vivo CRO market and is predicted to continue expanding over the coming years.

Model Insights

In 2022, the Oncology Based In-vivo CRO market was dominated by the Syngeneic segment, which held the largest revenue share of 70.82%.

Regional Insights

The North America region has established itself as the leader in the Oncology Based In-vivo CRO Market with a significant revenue share of 37% in 2022.

Recent Developments

• Toenhance the commercialization and development of the OmniCAR cell therapytechnology, Thermo Fisher Scientific Inc. and Prescient Therapeuticsestablished a partnership in August 2022. This agreement would evaluate thepotential of using automated closed-cell therapy options to develop a specialmethod for making cell treatments on the OmniCAR platform without the usage ofviruses.
• ElicioTherapeutics received a USD 2.8 million grant from the Gastro-IntestinalResearch Foundation (GIRF) in Chicago in September 2022 to support thedevelopment of two therapeutic cancer vaccines. While ELI-008 is beingdeveloped to target p53 hotspot mutations in solid tumours such colorectalcancer, melanoma, and non-small cell lung cancer (NSCLC), ELI-007 is beingdeveloped to target BRAF gene alterations. As a result, the COVID-19 pandemichas influenced the in-vivo CRO market for oncology.
• BioanalyticalSystems, Inc. debuted Inotiv, its new brand for contract research services, inNovember 2021. Beginning with in vivo toxicology, pharmacology, bioanalysis,drug metabolism, and pharmacokinetic solutions, Inotiv began representing theunification of the business' Seventh Wave Laboratories & Smithers AvanzaToxicology Services.

Key Market Players

• Charles River Laboratories, Inc.
• ICON PLC
• Thermo Fisher Scientific Inc.
• Eurofins Scientific SE
• Taconic Biosciences, Inc.
• Crown Biosciene, Inc.
• LabCorp
• WuXi AppTec Co., Ltd.
• Evotec SE
• The Jackson Laboratory